The 9th issue of my Newsletter is out!
I dive into how pharma is moving to big bets and I explore an interesting study on competitive feedback loops in LLMs, and the emergence of “AI workslop”, among other things
https://t.co/IaRTnynWgB
Issue #7 of my newsletter is out
It's been a busy week in AI and life sciences:
- Pharma isn’t just buying AI — it’s building the AI ecosystem.
- The UK risks falling behind as big R&D bets stall.
- The next AI race isn’t size, it’s reliability.
https://t.co/yLTkdL5RsA
New issue: The Great Divergence — AI Healthtech Splits from the Pack
💸 Chai $70M, Ambience $243M
🏛 FDA clears path for adaptive AI
🏥 Epic & GE launch AI tools
🌍 Novo Nordisk hits Denmark’s GDP
https://t.co/llV38oJmce
#AI#Healthcare#Biotech
AI in medicine isn’t just a tech race anymore. It’s a sovereignty race.
Data, compute & models = strategic assets.
In the first issue of Noor's Newsletter, I cover key Bio-AI shifts.
👇 https://t.co/MVlq8lQ8wM
#BioAI#Sovereignty#HealthTech
Reflecting on a decade of AI in drug discovery—what we've learned, where we're headed. I’ve written a short piece on the past 10 years and the road ahead. Read it here: https://t.co/4tIcDvZ6l2
Thrilled that our two papers got accepted for #DDW2025! 🚀 Our AI system accurately quantifies inflammation & diagnoses cancer—key for better disease management.
Huge thanks to our amazing collaborators: Prof. @PancPathologist, @NuhaShaker, (@UPMC), & Haider Mejbel (Emory)!
Replace ELECTRICITY with AI and this ad from 1899 still holds.
ELECTRICITY lights our city.
ELECTRICITY runs our street cars.
ELECTRICITY causes wagons without horses to go.
ELECTRICITY will do our cooking and heating.
ELECTRICITY will soon do everything.
Excited to join King's College London’s advisory board for the Industrial Collaborative Awards in Science and Engineering (iCASE) program! Focusing on bridging the gap between groundbreaking research and industrial-scale transformations!
There’s something genuinely exciting about witnessing AI bring new insights to life- accurately at scale.
@SPATIALX_AI building specialized foundation AI models to match the complexity of disease biology, and the depth of information we can uncover is mind-blowing! #AIPAthology
Thrilled to announce Boltz-1, the first open-source and commercially available model to achieve AlphaFold3-level accuracy on biomolecular structure prediction! An exciting collaboration with @jeremyWohlwend, @pas_saro and an amazing team at MIT and Genesis Therapeutics. A thread!
I had a “conversation” with none other than Henry Ford!
You can listen to it on Spotify here:
https://t.co/Bqtjpn3ys7
Using AI, I brought Henry Ford’s story to life, here is how:
1️⃣ ChatGPT and Claude for generating and fact-checking
2️⃣ ChatGPT for Voice
3️⃣ Ideogram for art
In a public debate, it is the one whose intelligence is closest to that of the audience who wins*.
*In other words: usually (in politics or academic psychology), the most stupid; in rare cases (say, in mathematics, physics, cooking/bartending schools), the most intelligent.
Excited that our work on spatial tissue analysis with USCF, OSU, and UPMC was presented at PathVisions this week. If you missed our papers, please reach out to learn how our AI spatial biomarkers are driving insights in clinical decision-making. #PathVision24#AIPAthology
I think the standard biotech PR strategy is dumb:
1. Launch with an exceptional team and a huge pot of cash.
2. No public updates for ~3-4 years.
3. Fold quietly.
Seems hugely harmful to science and careers of the founders+employees. Public outputs are important.